Legal Disclaimers 2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995
Wednesday, June 26, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: EyePoint Pharmaceuticals announced favorable preliminary results for DURAVYU from the Phase 2 DAVIO 2 clinical trial. The data indicates no serious adverse events associated with DURAVYU, and there were no occurrences of insert migration or retinal occlusive vasculitis. The patient discontinuation rate was low, with none of the discontinuations related to the treatment. This positive safety profile suggests potential for further development of DURAVYU in ocular treatments.
Price reaction · baseline $8.26 (2024-06-25 close) · hit after-hours · clean, no other EYPT news in the window
day 0 close
-0.8%
Market Sentiment Analysis
POSITIVE FACTORS
DURAVYU demonstrated a favorable safety profile in the clinical trial.
No serious adverse events related to DURAVYU were reported.
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+28%
120-day peak, hindsight
Typical move
53.1%
average across 5 past catalysts
Cash runway
~8 mo
Medium dilution risk
Lead asset
EYP-1901
Phase 3 · Wet Age Related Macular Degeneration
Full Press Release Details
DURAVYU Demonstrated a Favorable Safety Profile in the Phase 2 DAVIO 2 Clinical Trial No DURAVYU-related ocular or systemic SAEs No insert migration into the anterior chamber No retinal occlusive vasculitis Low patient discontinuation rate No discontinuations were related to DURAVYU treatment 1. As deemed by the investigator Data as of June 14, 2024 SAE, serious adverse event; AE, adverse event; IVT, intravitreal injection PRELIMINARY DATA CUT PENDING FINAL ANALYSIS
Frequently Asked Questions
What safety profile did DURAVYU demonstrate?
DURAVYU showed a favorable safety profile in the Phase 2 trial.
Were there any serious adverse events related to DURAVYU?
No DURAVYU-related ocular or systemic serious adverse events occurred.
Did any patients discontinue DURAVYU treatment?
There was a low patient discontinuation rate, with no related to DURAVYU.
Was there any retinal occlusive vasculitis reported?
No cases of retinal occlusive vasculitis were reported in the trial.
What is the status of the trial data?
The preliminary data cut is pending final analysis.